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Background: Limited evidence exists regarding the long-term performance of polymer-
free (PF) drug-eluting stents (DES) in comparison to permanent polymer DES. This
study investigated the 5-year efficacy and safety of a PF sirolimus-eluting stent (PF-
SES) versus a permanent polymer paclitaxel-eluting stent (PES) in the setting of the
Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between Two
Drug-Eluting Stents (ISAR-TEST) randomized trial. Methods and Results: A total of 450
patients undergoing percutaneous coronary intervention were randomized to receive ei-
ther PF-SES (Yukon, Translumina; n 5 225) or PES (Taxus, Boston Scientific; n 5 225).
Clinical follow-up was performed to 5 years after enrollment. The endpoints were major
adverse cardiac events (MACE), target lesion revascularization (TLR), the composite of
death or any myocardial infarction (MI) and stent thrombosis (ST). The incidence of
MACE at 5 years was 27.3% (57 patients) in the PF-SES group and 31.7% (65 patients) in
the PES group [hazard ratio (HR) 5 0.87 [95% confidence interval (95% CI) 5 0.61–1.24];
P 5 0.40]. The combined incidence of death or MI was 16.6% (34 patients) in the PF-SES
group and 20.0% (39 patients) in the PES group (HR 5 0.86 [95% CI 5 0.54–1.36]; P 5
0.52). The incidence of TLR was 16.5% (34 patients) in the PF-SES group and 16.4% (33
patients) in the PES group (HR 5 1.03 [95% CI 5 0.64–1.66]; P 5 0.89). ST occurred in
0.5% (one patient) in the PF-SES group and 1.6% (three patients) in the PES group (HR
5 0.33 [95% CI 5 0.03–3.14]; P 5 0.32). Conclusion: Overall there was no significant differ-
ence in clinical outcomes between PF-SES and PES to 5 years. Extended follow-up supports
the durability of efficacy and safety of PF-SES. VC 2012 Wiley Periodicals, Inc.
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INTRODUCTION
Drug-eluting stents (DES) demonstrate superior per-
formance to bare metal stents in terms of antirestenotic effi-
cacy and reduced need for revascularization [1]. However
concern exists relating to a higher risk of stent thrombosis
(ST) very late after stent implantation (>12 months) as
well as to a gradual delayed erosion of antirestenotic effi-
cacy—both clinical conditions related to the pathophysio-
logical spectrum of delayed arterial healing [2–6].
1Deutsches Herrzentrum, Technische Universitãt, Munich, Ger-
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Permanent polymer coating is used to bind antireste-
notic drug to the stent platform and to facilitate con-
trolled drug release in DES; however, these coatings
remain in situ following drug elution. Human postmor-
tem and animal studies have demonstrated an inflam-
matory response to polymer residue [7,8], and this may
have a causal role in the etiology of delayed arterial
healing, the substrate, which is thought to underlie
both late ST (LST) and late restenosis [9–13].
The ISAR-TEST clinical trial compared a polymer-
free sirolimus-eluting stent (PF-SES) with a permanent
polymer paclitaxel-eluting stent (PES) in 450 random-
ized patients undergoing elective percutaneous coronary
revascularization (PCI) in native vessels. The primary
analyses have been previously reported and demon-
strated that PF-SES and PES had equivalent efficacy
and safety at 1 year [14]. However it is not known if
the efficacy of PF-SES is maintained over the medium-
and long-term or whether a clinical advantage over
permanent polymer stents will emerge with extended
clinical follow-up. The objective of this study was to
directly the compare the 5-year safety and efficacy out-
comes in the patient groups treated with PF-SES and
polymer-based PES in the ISAR-TEST clinical trial.
METHODS
Study Population and Device Description
Details of the ISAR-TEST study design, methods
and patient population have been reported previously
[14]. Briefly, the ISAR-TEST trial was a prospective,
randomized, investigator-initiated trial conducted at
two centers in Munich, Germany. Patients were eligible
for inclusion if greater than 18 years old with symp-
toms of angina or objective evidence of coronary is-
chemia and with de-novo stenosis of a native coronary
artery  50%. Patients were considered ineligible for
the study if the target lesion was in the left main stem,
cardiogenic shock was present, a myocardial infarction
(MI) occurred within the 48 hr prior to enrollment, any
malignancy or any comorbidity limiting life expectancy
to less than 12 months was evident, contraindications
existed to the main study medications (including siroli-
mus, paclitaxel, aspirin, heparin, stainless steel and clo-
pidogrel), or if pregnancy was confirmed, suspected or
planned. The study protocol was approved by the insti-
tutional Ethics Committee responsible for both partici-
pating centers. All patients gave their written informed
consent for participation in this trial.
Randomization was performed after successful wiring
of the target vessel and this was considered time zero in
the study. Treatment allocation was made using sealed
opaque envelopes containing a computer-generated
sequence. Randomization was not stratified. Patients
were allocated to both groups concurrently and in equal
numbers. The same assigned stent was implanted in all
lesions in those patients with multiple lesions or with
lesions requiring multiple stents. Patients were assigned
to receive either a PF-SES (Yukon stent [Translumina,
Hechingen, Germany]) or PES (Taxus stent, Boston
Scientific, Natick, MA).
The PF stent platform consisted of a premounted,
sand blasted, 316-L stainless steel microporous stent,
which is coated on-site with sirolimus. A detailed
description of the coating process, the sirolimus elution
characteristics and the drug release profile of the per-
manent polymer stent are reported elsewhere [15,16].
Study Protocol
A 600-mg loading dose of clopidogrel was given at
least 2 hours prior to undergoing cardiac catheteriza-
tion. Following the procedure, aspirin 200 mg per day
was prescribed indefinitely and clopidogrel 150 mg per
day until hospital discharge and then 75 mg daily for
at least 6 months. Other medications (ß-blockers,
statins and ACE inhibitors) were prescribed as appro-
priate. Repeat coronary angiography was performed at
6–8 months or earlier if symptoms indicated.
Patients received follow-up telephone interviews at
one and 9 months and then annually from year 1 to
year 5. If chest pain or cardiac symptoms were
reported during follow-up then patients were advised to
consult their referring physician.
Data Management, Endpoints, and Definitions
Relevant data were collected and entered into a com-
puter database by specialized personnel of the Clinical
Data Management Center. All data were verified
against source documentation, and all adverse events
were adjudicated by an event verification committee
blinded to treatment allocation. The primary endpoint
for the present analysis was a composite endpoint of
major adverse cardiac events (MACEs) consisting of
all-cause death, any MI or target lesion revasculariza-
tion (TLR) at 5 years post-enrollment. Secondary end-
points were the composite of death or any MI, definite
or probable ST and TLR.
TLR was defined as any ischemia-driven repeat PCI
of the target lesion or bypass surgery of the target vessel.
Deaths were classified as cardiac or noncardiac accord-
ing to hospital records, death certificates and telephone
calls with the attending physician or the relatives. Car-
diac death was defined as death due to any of the follow-
ing: acute MI; cardiac perforation/pericardial tampon-
ade; arrhythmia or conduction abnormality; stroke
within 30 days of the procedure or stroke suspected of
being related to the procedure; death due to complication
E24 King et al.
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
of the procedure, including bleeding, vascular repair,
transfusion reaction, or bypass surgery; or any death in
which a cardiac cause could not be excluded.
MI related to procedure was defined as either an
increase in CK-MB (or CK)  3 upper limit of normal
(ULN) and at least 50% over the most recent pre-PCI lev-
els, or the development of new ECG changes consistent
with MI and CK-MB (CK) elevation higher than the ULN
at two measurements for patients undergoing DES im-
plantation in setting of stable angina pectoris or non-ST-
segment elevation acute coronary syndrome and falling or
normal CK-MB (CK) levels. Bypass surgery related MI
was considered either CK-MB elevation  10 ULN and
at least 50% over the most recent presurgery levels or
CK-MB elevation  5 ULN and at least 50% over the
most recent presurgery levels in addition to new abnormal
Q-waves on the ECG. ST was classified according to Aca-
demic Research Consortium (ARC) criteria [17].
Statistical Methods
The objective of this study was to assess the safety
and efficacy of the PF-SES stent when compared with
the PES at 5 years. Sample size calculation was based
on the assessment of late lumen loss at follow-up angi-
ography and has been described previously [14]. The
analysis was performed on an intention-to-treat basis.
In patients with multilesion interventions, only the first
treated lesion was included in the analysis. Continuous
data are presented as mean (SD) or median (25th to
75th percentiles), and compared using Student’s t-test
or Wilcoxon rank-sum test. Categorical data are pre-
sented as counts or proportions (%) and compared
using chi square or Fisher’s exact test. Survival was
assessed using the methods of Kaplan-Meier and sur-
vival parameters were compared using Cox’s propor-
tional hazards model to calculate hazard ratios (HR)
with 95% confidence intervals (CI) for PF-SES
compared with PES. A two-sided P-value < 0.05 was
considered statistically significant.
Statistical software S-PLUS, version 4.5 (S-PLUS,
Insightful Corp, Seattle, WA) was used for analysis.
RESULTS
A total of 450 patients were enrolled in the study,
225 received the PF-SES and 225 were treated with the
PES. The baseline clinical, angiographic and procedural
characteristics were well matched in both groups (Table
I). No patients were lost to follow-up during the study.
Clinical outcomes at 5 years are shown in Table II.
There were no significant differences in MACEs, the
primary composite endpoint (Fig. 1). The rate of TLR
at 5 years did not differ significantly between groups
(Fig. 2). Outcomes for the composite endpoint of death
or MI were also similar and are shown in Fig. 3. One
patient in the PF-SES group developed acute ST within
the first 30 days (0.5%), however there were no further
episodes of definite ST associated with the PF stent at
5 years. Three patients in the PES group developed ST
(1.6%), comprising of one episode within the first
30 days, one episode within the first year and one
episode within the fourth year (HR ¼ 0.33 [95% CI ¼
0.03–3.14], P ¼ 0.32).
DISCUSSION
The ISAR-TEST trial was a two-center randomized
trial comparing the safety and efficacy of a novel PF-SES
with a first-generation polymer-based PES. The present
analysis represents the first report of extended follow-up
with PF versus permanent polymer stents. The 5-year fol-
low-up results provide several points of interest regarding
both safety and efficacy: (i) overall clinical outcomes
were similar with both stents; (ii) the equivalence in
safety previously reported at 1 year was maintained to 5
years. Adverse events rarely occurred beyond 1 year for
both PF-SES and PES. Of note, there were no ST beyond
30 days in the group treated with PF-SES; and (iii) regard-
ing efficacy the equivalence in rates of TLR observed at 1
year was maintained to 5 years.
The safety outcomes for the PES are in keeping with
long term findings previous PES trials [18,19]. The
best evidence currently available concerning PF stents
largely consists of data up to 2 years in clinical trials
designed primarily to assess noninferiority of angio-
graphic outcomes in comparison to both permanent-
polymer DES and biodegradable-polymer DES
[20–25]. This group has previously demonstrated that a
PF-SES stent had equivalent antirestenotic efficacy and
safety to both a biodegradable-polymer SES and a per-
manent-polymer SES at 2 years both in a randomized
controlled trial of 605 patients [21], and in a larger
real world, nonrandomized, prospective trial of 2588
patients [2].
However there is no reported data on the long-term
safety and efficacy of DES with polymer-free technology.
Such late comparative performance is important. Given
the differences in design between the stent platforms it is
reasonable to question whether late performance may dif-
fer. The equivalent safety profile and equivalent efficacy
at 5 years between the PF-SES and the PES demonstrated
in this study are, therefore, important findings.
There is significant evidence that an inflammatory
response to the residue from permanent polymers con-
tributes toward delayed arterial healing following DES
implantation [7,8], and that this may be a significant
factor in the incidence of LST seen with DES [9–13].
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Although the rate of ST was lower in the PF-PES
group, and there was no ST in the PF-SES group
beyond 30 days, this study was not powered to detect
differences in rare adverse events such as ST.
LIMITATIONS OF THE STUDY
Although follow-up angiography during the first year
provides useful information regarding lumen renarrowing,
clinical follow-up is preferable for evaluating long-term
TABLE 2. Clinical Outcomes at 5 Years
PF-SES PES Hazard ratio P-value
Patients 225 225
Death, MI, or TLR (MACEs) 57 (27.3) 65 (31.7) 0.87 [0.61–1.24] 0.40
Death or MI 34 (16.6) 39 (20.0) 0.86 [0.54–1.36] 0.52
TLR 34 (16.5) 33 (16.4) 1.03 [0.64–1.66] 0.89
Stent thrombosis 1 (0.5) 3 (1.6) 0.33 [0.03–3.14] 0.32
Cardiac death or MI 30 (14.9) 27 (13.9) 1.10 [0.65–1.85] 0.67
MI 17 (8.1) 10 (5.0) 1.70 [0.78–3.71] 0.16
All-cause death 20 (10.2) 31 (16.2) 0.63 [0.36–1.10] 0.10
Cardiac death 16 (8.4) 19 (10.1) 0.82[0.42–1.59] 0.60
Data are shown as number (percentage) by Kaplan–Meier analysis; hazard ratios [95% confidence interval] were calculated using Cox’s proportional.
Hazards model. DES, drug-eluting stent; MACEs, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel-eluting stent; PF-SES,
polymer-free sirolimus-eluting stent; TLR, target lesion revascularization.
TABLE 1. Demographic, Clinical, Angiographic, and Procedural Patient Characteristics
PF-SES PES P
Patients 225 225
Age (yr) 66.8  10.5 66.6  10.2 0.88
Women (n; %) 56 (25) 48 (21) 0.37
Diabetes mellitus (n; %) 73 (32) 58 (26) 0.12
Current smoker (n; %) 43 (19) 39 (17) 0.63
Arterial hypertension (n; %) 142 (63) 155 (69) 0.20
Hypercholesterolemia (n; %) 165 (73) 170 (76) 0.59
Unstable angina (n; %) 94 (42) 99 (44) 0.63
Prior MI (n; %) 72 (32) 71 (32) 0.92
Prior aortocoronary bypass surgery (n; %) 25 (11) 25 (11) 1.0
Left ventricular ejection fraction (%) 54.0  14.1 55.3  13.5 0.33
Number of lesions treated 1.2  0.44 1.1  0.36 0.13
Target vessel 0.48
Left anterior descending coronary artery (n; %) 88 (39) 96 (43)
Left circumflex coronary artery (n; %) 78 (35) 66 (29)
Right coronary artery (n; %) 59 (26) 63 (28)
Complex (type B2/C) lesions (n; %) 168 (75) 176 (78) 0.37
Vessel size (mm) 2.72  0.46 2.73  0.49 0.94
Lesion length (mm) 12.6  5.9 12.9  7.0 0.59
Minimal lumen diameter procedure (mm) 1.14  0.40 1.14  0.42 >0.99
Diameter stenosis prior to procedure (%) 58.3  12.4 58.1  12.7 0.87
Number of stents per lesion 1.16  0.38 1.08  0.26 0.006
Minimal lumen diameter after procedure 2.57  0.43 2.59  0.42 0.61
Diameter stenosis after procedure 9.0  5.9 8.7  7.0 0.63
Late lumen loss
In-stent (mm) 0.48  0.61 0.48  0.58 0.98
In-segment (mm) 0.34  0.59 0.24  0.57 0.09
Minimal lumen diameter
In-stent (mm) 2.10  0.68 2.11  0.70 0.96
In-segment (mm) 1.93  0.65 1.93  0.68 0.98
Diameter stenosis
In-stent (%) 25.04  20.79 25.66  19.28 0.77
In-segment (%) 31.64  18.84 31.97  18.72 0.87
Angiographic restenosis
In-stent (n; %) 23 (12.6) 21 (11.6) 0.78
In-segment (n; %) 26 (14.2) 28 (15.5) 0.73
Values are mean  SD or n (%). PF-SES, polymer-free sirolimus-eluting stent; PES, paclitaxel-eluting stent.
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device performance. However, this trial was powered to
detect primary angiographic outcomes at 6-8 months and
comparisons beyond this time point, as well as relating to
clinical outcomes, should be regarded as post hoc and
hypothesis generating. Furthermore, it should be acknowl-
edged that the current report is not powered to detect dif-
ferences in rarely occurring clinical events such as MI and
LST. As such, it is not able to assess noninferiority or su-
periority of long term safety or efficacy. Aggregate analy-
sis of large scale long-term trials may provide the means
to effectively address the issues of LST and long-term
safety in general. In addition, although clinical follow-up
was performed by specialized personnel of the Clinical
Data Management Center, telephone follow-up might not
be sensitive enough to capture oligo- or asymptomatic
MI. The reported results relate to a general population
undergoing elective PCI in the context of a clinical trial.
Larger scale prospective observational and registry data
may also contribute to our understanding of the perform-
ance of PF stents outside of the clinical trial setting and
may provide insight into outcomes of the use of PF stents
in high-risk patients and in high-risk lesions. The com-
parator stent used in this study was a first-generation PES
which although now used relatively infrequently in clini-
cal practice, was in routine clinical use at the time the
study was undertaken.
CONCLUSION
The 5-year follow-up of the ISAR-TEST study dem-
onstrates equivalent long-term efficacy and safety
between a PF-SES and a permanent-polymer PES.
These findings provide a sound basis to test the
hypothesized late performance advantage of this tech-
nology in large-scale studies powered for clinical end-
points.
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